FEAF
TPEx

4903 聯光通

48.50 ▲ 0.50 (1.04%) Close · 2026-11-13 · TPEx
Ask about 4903
This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.

Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.

Your risk profile
Conclusion

Mixed picture: 3 strengths against 2 watch-outs. Weigh them against your own goals.

Points to watch for a moderate profile: see the items marked above.

No model narrative: the model call failed. The structured analysis above is complete on its own.

Strengths

+ Revenue grew 64.5% in 2025; latest quarter Q3 2026: 0.1% year on year. source (Financials) →
+ Liabilities are only 39.7% of total assets (Q3 2026): a light debt load. source (Financials) →
+ Free cash flow was positive in 2025: 97 NT$ million. source (Financials) →

Watch-outs

! The current price implies 4.2% perpetual growth, above the 3.5% ceiling: the price already assumes high expectations. source (Valuation) →
! Return on equity 5.1% with a 3.8% net margin: weak profitability. source (Key Stats) →

What to check before deciding

?Can the company sustain growth above the perpetual-growth ceiling for years?
?What would lift profitability, and how soon?

What the analysis found

! Valuation (DCF) The current price implies 4.2% perpetual growth, above the 3.5% ceiling: the price already assumes high expectations. source →
+ Growth Revenue grew 64.5% in 2025; latest quarter Q3 2026: 0.1% year on year. source →
! Profitability Return on equity 5.1% with a 3.8% net margin: weak profitability. source →
+ Debt Liabilities are only 39.7% of total assets (Q3 2026): a light debt load. source →
+ Cash flow Free cash flow was positive in 2025: 97 NT$ million. source →
· Filings 2 verified alert(s); latest on 2026-11-09: 公告本公司董事會決議辦理現金增資發行新股 source →
· Filings 1 filing(s) are held or rejected and wait for human review. source →